McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

Original reporting
Published Oct 8, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson & CD&R Acquire Leading US Home-Infusion Platform — source image
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The transaction provides McKesson with a foothold in outpatient infusion, expanding its specialty pharma logistics network.

02

Market read

Large M&A deal in healthcare distribution sector with immediate price impact potential for both acquirer and target.

03

What to watch

Regulatory approvals and integration risks could delay expected synergies.

Relevance 9/10Novelty 9/10Timing: today

Background

McKesson partners with private‑equity firm CD&R to acquire Option Care Health, a leading U.S. home‑infusion platform.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson announced a $5.8bn acquisition of Option Care Health, taking a minority stake worth $1.4bn.

Expected impact

likely upward pressure as investors price in strategic expansion and cash deployment.

Evidence & confidence

Large‑scale M&A with clear strategic rationale; market typically rewards such announcements.

Market effects

Strengthens the home‑infusion and specialty pharma distribution sector, signaling consolidation and potential margin expansion.

U.S. healthcare distribution market may see increased M&A activity as firms seek scale.

Highlights growing importance of outpatient infusion services worldwide.

Counterpoint

Deal could strain McKesson's balance sheet and distract from core distribution business.

Key entities

  • McKesson

    U.S. healthcare distributor and acquirer.

  • Option Care Health

    Provider of outpatient infusion services.

  • Clayton, Dubilier & Rice

    Majority stakeholder in the transaction.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.